Low Molecular Weight Heparin: A Practical Approach in Deep Venous Thrombosis in Palliative Care

INTRODUCTION: Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin. AIMS: Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical u...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutta, Samrat, Chattopadhayay, Subrata, Dasgupta, C, Sarkar, Shyamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183604/
https://www.ncbi.nlm.nih.gov/pubmed/21976855
http://dx.doi.org/10.4103/0973-1075.84536
Descripción
Sumario:INTRODUCTION: Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin. AIMS: Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical utility in palliative care settings. MATERIALS AND METHODS: Twelve cases of established DVT received enoxaparin at 40 mg/m with warfarin. RESULTS: There was 70% resolution of limb swelling in seven cases. Out of remaining four cases took two months to resolve and one case did not resolve completely. CONCLUSIONS: LMV heparin is effective in palliative care setting and also has added advantage of subcutaneous route of administration.

Ejemplares similares